Aetna Inc. (AET) Upgraded to “Outperform” at Raymond James Financial, Inc.
Raymond James Financial, Inc. upgraded shares of Aetna Inc. (NYSE:AET) from a market perform rating to an outperform rating in a research note published on Friday morning. They currently have $200.00 price target on the stock.
Several other equities analysts have also issued reports on AET. Credit Suisse Group reaffirmed an outperform rating and set a $165.00 price target (up previously from $160.00) on shares of Aetna in a research note on Thursday, July 13th. Deutsche Bank AG upped their price target on Aetna from $144.00 to $157.00 and gave the company a hold rating in a research note on Thursday, July 13th. BidaskClub lowered Aetna from a strong-buy rating to a buy rating in a research note on Wednesday, July 19th. Royal Bank Of Canada upped their price target on Aetna from $162.00 to $171.00 and gave the company an outperform rating in a research note on Friday, August 4th. Finally, Jefferies Group LLC reaffirmed a hold rating and set a $163.00 price target (up previously from $157.00) on shares of Aetna in a research note on Friday, August 4th. Eleven equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $170.34.
Aetna (AET) traded up $4.67 during trading on Friday, reaching $176.99. The company’s stock had a trading volume of 5,650,000 shares, compared to its average volume of 2,701,255. The company has a current ratio of 0.53, a quick ratio of 0.48 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $57,716.44, a price-to-earnings ratio of 17.33, a P/E/G ratio of 1.61 and a beta of 0.61. Aetna has a one year low of $105.39 and a one year high of $184.98.
Aetna (NYSE:AET) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $2.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.39. Aetna had a return on equity of 21.84% and a net margin of 2.93%. The business had revenue of $14.99 billion for the quarter, compared to analyst estimates of $15.12 billion. During the same quarter in the prior year, the firm posted $2.07 earnings per share. The firm’s revenue for the quarter was down 5.0% compared to the same quarter last year. equities analysts forecast that Aetna will post 9.79 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Thursday, October 12th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, October 11th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.13%. Aetna’s payout ratio is presently 37.04%.
In related news, President Karen S. Lynch sold 15,271 shares of the stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $161.91, for a total transaction of $2,472,527.61. Following the completion of the transaction, the president now directly owns 64,261 shares in the company, valued at $10,404,498.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Margaret M. Mccarthy sold 10,288 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $162.85, for a total value of $1,675,400.80. Following the transaction, the executive vice president now owns 33,563 shares of the company’s stock, valued at $5,465,734.55. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of AET. Vanguard Group Inc. boosted its position in Aetna by 3.8% during the first quarter. Vanguard Group Inc. now owns 23,117,526 shares of the company’s stock valued at $2,948,640,000 after purchasing an additional 838,578 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Aetna by 117.5% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 35,141 shares of the company’s stock valued at $4,482,000 after purchasing an additional 18,983 shares during the last quarter. Geode Capital Management LLC boosted its position in Aetna by 8.6% during the first quarter. Geode Capital Management LLC now owns 3,539,245 shares of the company’s stock valued at $450,809,000 after purchasing an additional 279,133 shares during the last quarter. Becker Capital Management Inc. boosted its position in Aetna by 3.8% during the first quarter. Becker Capital Management Inc. now owns 340,914 shares of the company’s stock valued at $43,484,000 after purchasing an additional 12,473 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Aetna by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 3,962,514 shares of the company’s stock valued at $505,399,000 after purchasing an additional 21,953 shares during the last quarter. Institutional investors and hedge funds own 89.45% of the company’s stock.
Aetna Company Profile
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.